Revolve Wealth Partners LLC Sells 85 Shares of Zoetis Inc. (NYSE:ZTS)

Revolve Wealth Partners LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,199 shares of the company’s stock after selling 85 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Zoetis were worth $208,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ZTS. Vanguard Group Inc. grew its position in shares of Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after buying an additional 414,605 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Capital World Investors raised its holdings in Zoetis by 0.6% in the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after purchasing an additional 57,798 shares during the period. Norges Bank bought a new position in shares of Zoetis during the fourth quarter worth $980,646,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Zoetis by 3.5% in the 1st quarter. Bank of New York Mellon Corp now owns 4,509,599 shares of the company’s stock valued at $763,069,000 after buying an additional 151,689 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.2 %

NYSE ZTS traded down $0.37 during trading hours on Friday, hitting $183.71. 1,588,375 shares of the company traded hands, compared to its average volume of 2,759,420. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The business’s 50-day moving average is $177.78 and its 200-day moving average is $175.20. The stock has a market capitalization of $83.83 billion, a price-to-earnings ratio of 35.40, a P/E/G ratio of 2.81 and a beta of 0.86. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.41 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ZTS. BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. HSBC decreased their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Barclays dropped their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average price target of $217.11.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.